ArticleResearch in pharmaceutical sciences2025
The beneficial effect of gamma aminobutyric acid on diabetic nephropathy in type 2 diabetic rat model and their offspring.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The sleep-wake cycle: molecular mechanisms, disorders, and therapeutic targets in the context of energy metabolism.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Diabetic nephropathy (DN) in the first and second generations of diabetic rats and improving kidney function by gamma aminobutyric acid (GABA) were investigated. Experimental approach: Male and female rats and their offspring were used. Diabetes was induced by a high-fat diet and a low dose of streptozotocin. Animals were divided into the diabetic positive control (D) group, the diabetic group receiving insulin (D + insulin), and the diabetic group receiving GABA (D + GABA). In addition, two groups of non-diabetic parents were assigned as negative control (NDC) groups. Each animal was monitored for 16 weeks, and offspring were fed with normal diet. The blood glucose level, urine volume, and water intake, as well as renal function, including the serum levels of blood urea nitrogen (BUN), creatinine (Cr), and glomerular filtration rate (GFR) were assessed. Also, the hyperinsulinemic-euglycemic clamp and gene expressions of Findings/Results: GABA administration in parents and offspring decreased blood glucose level, insulin resistance, GFR, serum levels of BUN and Cr compared to the D groups. GABA reduced the urine Cr, BUN, and albumin loads in both parents and offspring in comparison to the D groups. GABA decreased Conclusion and implications: GABA decreased the risk of DN, hyperglycemia, and insulin resistance in both diabetic parents and their offspring by improving kidney function, highlighting the potential therapeutic benefits of GABA in managing type 2 diabetes complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.